- Home
- LSF vs MREO Comparison
LSF vs MREO Comparison
Compare LSF & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | MREO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 53.4M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LSF | MREO |
|---|---|---|
| Price | $4.44 | $0.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $6.00 | $1.50 |
| AVG Volume (30 Days) | 72.0K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | 16.67 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $49,889,286.00 | $500,000.00 |
| Revenue This Year | $90.82 | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $42.73 | ★ N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $1.96 | $0.20 |
| 52 Week High | $7.80 | $2.37 |
Technical Indicators
Market Signals| Indicator | LSF | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 48.41 |
| Support Level | $3.00 | $0.31 |
| Resistance Level | $5.11 | $0.35 |
| Average True Range (ATR) | 0.35 | 0.02 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 17.28 | 27.14 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).